Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 
Online Report Subscribers, Click Here
Pricing and Ordering Information
ClearState

China Asthma Drug Market Report 2008
Report #DHP9006 - May 2009

It is estimated that there were approximately 300 million asthma patients worldwide in 2004 and one out of every 250 disease-related deaths was caused by asthma. In China, the incidence rate of asthma has continuously increased in recent years, especially among urban children, with the latest surveys showing that the incidence rate is 0.7% - 1.5% in adults and 0.1% - 2.0% in children. Asthma is known as a costly disease that is difficult to cure. On average, asthma treatment will cost a patient over RMB 3000 per year in China. So, assuming a national asthma population of 15 – 18 million and a 10% treatment rate, the cost of asthma treatment is currently RMB 4.5 – 5.6 billion. In 1999, the Chinese asthma drug market was RMB 1.7 billion. By 2007, asthma drug sales had increased to approximatelyRMB 4.9 billion (USD 714 million), an increase of 22.1% from 2006 alone.

This new report thoroughly analyzes the Chinese asthma drug market. All of the drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitoring system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (China Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou and cover significant percentages of all hospitals in these regions. The comprehensive hospital utilization data of major asthma drugs provides a clear picture of the competitive landscape of the Chinese asthma drug market and the market potential for both products that are already marketed in China or those shortly to be launched in the Chinese marketplace. Market shares for all of the major competitors, including multinational and Chinese pharmaceutical companies and their major asthma products, are presented within this meticulously-researched report.

Ordering Information

Title

 Report# Publication
Date		 List Price

China Asthma Drug Market Report 2008

DHP9006

 May 2009

$4,500
Order Online:
Single User only (Please call for corporate subscription pricing)		     PDF Only

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

Top 20 Pharmaceutical Companies in the Chinese Asthma Drug Hospital Market

 

Methodology

 

Chapter I.        Clinical Application of Asthma Drugs

Section 1.   Definition of Asthma

1.1 Definition

1.2 The Relationship of Asthma Airway Pathology and Impaired Pulmonary Function

Section 2.   Risk Factors of Asthma

Section 3.   Diagnosis and Classification of Asthma

3.1 Diagnosis of Asthma

3.2 Classification of Asthma

Section 4.   Treatment of Asthma

4.1 Management Plans Are Based on Asthma Control Levels

4.2 New Status of Certain Asthma Drugs

4.3 Dose Reduction for Maintenance Therapy

Section 5.   Common Asthma Drugs

5.1 Glucocorticoids Drugs

5.2 Theophylline Drugs

5.3 β-2 Receptor Agonists

5.4 The M-receptor Blockers

5.5 α-receptor Blocker

5.6 Anti-allergic Drugs

5.6.1 The H1 receptor blocker

5.6.2 Anaphylactic Mediator Blockers

5.6.3 Leukotriene-interfering Drugs

5.7 Antibiotics

5.8 Non-steroidal Anti-inflammatory Drugs (NSAIDs)

5.9 Diuretics

5.10 Other Inflammatory Mediator Antagonists and Cytokine Antagonists

5.11 Marrow Acidophil Progenitor Cell Inhibitors

5.12 Allergen Specific Immunotherapy (AIT)

5.13 Gene Therapy

 

Chapter II.      Analysis of the Chinese Asthma Drug Market

Section 1.   Market Size of the Chinese Asthma Drug Hospital Market

1.1 Epidemiology of Asthma in China

1.2 Theoretical Size of the Asthma Drug Market in China

1.3 Market Sizes and Annual Growth Rates of the Actual Asthma Drug Market in China (2003-2007)

Section 2.   Market Shares of the Top 20 Asthma Drugs in China (2005-2007)

Section 3.   Market Shares of Top 20 Pharmaceutical Companies in the China’s Asthma Drug Market (2005-2007)

Section 4.   Annual Growths of Market Shares of Top 20 Asthma Drugs in China (2005-2007)

Section 5.   Market Potential of the Top 20 Asthma Drugs

 

Chapter III.     Analysis of Brand Asthma Drugs in China

Section 1:  Market Shares of the Top 10 Branded Asthma Drugs in China

Section 2:  Major Manufacturers of Asthma Drugs and Their Key Products in China

GSK

AstraZeneca

Merck

Boehringer Ingelheim

Sankyo

Heilongjiang Fuhe Huaxing

Otsuka Pharmaceutical Ltd

 

Chapter IV.     R&D of Asthma Drugs

Section 1.   Conventional Medicines

1.1 Glucocorticoids

1.2 β-2 Receptor Agonist

1.3 M-receptor Blocking Agent

1.4 Theocin Category

1.5 Anti-leukotrienes medicine

1.6 Cromolyn sodium category

1.7 Antihistamine

Section 2.   Non-conventional Medicines

Section 3.   Immunotherapy

3.1 Specific Immunity Treatment (SIT)

3.2 BCG Vaccine (Bacillus Calmette-Guerin)

3.3 IL-4 and IL-5 Inhibitors

3.4 Anti-IgE Therapy

3.5 Neurokinin (NK) Receptor Antagonist

3.6 Others

Section 4.   Gene Therapy

Section 5.   Chinese Medicine Treatment

Section 6.   Other Therapies

 

Chapter V.       Brand Names, Manufacturers, and Formulas of Asthma Drugs in China

Section 1.   Brand Names, Chemical Names, Manufacturers and Formulas of Asthma Drugs in China

 

Chapter VI.     Prices of Asthma Drugs, and Asthma Drugs on the Chinese National Healthcare Insurance List

Section 1:  Formulas, Packages, Retail prices, Manufacturers (for Branded Drugs only) of Asthma Drugs in China

Section 2.   Asthma Drugs on the Chinese National Healthcare Insurance List

2.1. Chemical Drugs on the National Healthcare Insurance List

2.2. Traditional Chinese Medicines (TCMs) on the National Healthcare Insurance List

 

Appendix

 

Tables:

Table 1.      Classification of Asthma Prior to Treatme

Table 2.      Control Levels of Asthma

Table 3.      Market Shares of Top 20 Asthma Drugs in China 2005-2007

Table 4.      Annual Sales of Top 20 Asthma Drugs in China 2005-2007

Table 5.      Market Shares of the Top 20 Manufacturers of Asthma Drugs 2005-2007

Table 6.      Sales of Asthma Drugs from the Top 20 Manufacturers 2005-2007

Table 7.      Sales Growth of the Top 20 Asthma Drugs 2006-2007

Table 8.      Market Shares of GSK Brand Asthma drugs in the Chinese Hospital Market 2003-2007

Table 9.      Sales of GSK Brand Asthma drugs in the Chinese Hospital Market 2003-2007

Table 10.    Branded Asthma Drugs by AstraZeneca

Table 11.    Market Shares of AstraZeneca Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 12.    Sales of AstraZeneca Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 13.    Market Shares of Merck Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 14.    Sales of Merck Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 15.    Market Shares of Boehringer Ingelheim Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 16.    Sales of Merck Boehringer Ingelheim Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 17.    Market Shares of Sankyo Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 18.    Sales of Sankyo Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 19.    Market Shares of Fuhe Huaxing Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 20.    Sales of Fuhe Huaxing Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 21.    Market Shares of Otsuka Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 22.    Market Shares of Otsuka Brand Asthma Drugs in the Chinese Hospital Market 2003-2007

Table 23.    Brand Names, Chemical Names, Manufacturers and Formulas of Asthma Drugs in China

Table 24.    Formulas, Packages, Retail prices, Manufacturers (for Branded Drugs only) of Asthma Drugs in China

Table 25.    Chemical Drugs on the Chinese National Healthcare Insurance List

Table 26.    Traditional Chinese Medicines (TCMs) on the National Healthcare Insurance List

 

Figures:

Figure 1.    Asthma Management Map

Figure 2.    Market Sizes of the Chinese Asthma Drug Market (2003-2007)

Figure 3.    Market Potentials of the Top Asthma Drugs, China, 2007

Figure 4.    Market Shares of the Top 10 Asthma Drugs 2006

Figure 5.    Market Shares of the Top 10 Asthma Drugs 2007

Figure 6.    Sales of GSK Asthma Drugs 2005, 2006 and 2007

Figure 7.    Sales of Branded Asthma Drugs from AstraZeneca 2005, 2006 and 2007

 

Top 20 Pharmaceutical Companies in the Chinese Asthma Drug Hospital Market

(at least > 0.53% of the total Chinese Asthma Drug Hospital Market)

 

·         Boehringer Ingelheim

·         Zhejiang Beisheng

·         AstraZenaca

·         GSK

·         Guangdong Huanqiu

·         Guangzhou Maite-Xinghua

·         Guilin Nanyao

·         Hangzhou MSD China

·         Heilongjiang Fuhe Huaxing

·         Henan Kaifeng Kangnuo

·         Hengyang Hengsheng

·         Jiangsu China Medicine and Technology University

·         Otsuka Pharmaceutical Co Ltd

·         Qingzhou Yaowang

·         Sankyo

·         Shandong Hualu

·         Shandong Ruiyang

·         Shanghai Ethypharm

·         Sichuan Chengdu Huayu

·         Zhejiang Changxing

 

 

Draco Healthcare Consulting is the leader in the China-focused healthcare consulting business. They serve leading pharmaceutical and biotech companies both inside and outside of China to make better medicines for China. www.dracohealthcare.com

To order reports or obtain information about special pre-publication offers from within the U.S., contact sales@medtechinsight.com. From outside the U.S., contact internationalsales@medtechinsight.com. You can also call 1.949.453.0071 (or toll-free within the U.S. at 1.888.290.2225) or fax 1.949.453.0072.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home